86 Geschäftsbericht 2020 Lindenhofgruppe Lehre und Forschung Pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer (IBCSG 48-14 Positive). A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 24-02 BIG 2-02 SOFT) A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 25-02 BIG 3-02 TEXT) Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study (IBCSG 43-09 HoHo) Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 in patients with bone metastases from castration resistant prostate cancer or from breast cancer (SAKK 96/12 REDUSE) Analysis of clinical outcomes of therapy with Ranibizumab and Aflibercept compared to steroids in diabetic macular edema (ID: 2017-00143) Retrospective analysis of clinical outcomes after switching from Ranibizumab to Aflibercept (KEK-Nr. 099 / 15) An open-label, randomized, active-controlled, parallelgroup, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) (AZURE 16598) Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner/ Sponsor Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Campus Stiftung Lindenhof Bern (SLB) Ophthalmologie Prof. Dr. med. Justus Garweg - Ophthalmologie Prof. Dr. med. Justus Garweg - Ophthalmologie Prof. Dr. med. Justus Garweg Bayer
RkJQdWJsaXNoZXIy MzQxOTE=